Genetics of psoriatic arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 28, Issue 5, 2014, Pages 673-685

  O'Rielly, Darren D ^c   Rahman, Proton ^a,b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b St Clare's Mercy Hospital   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Candidate genes; Genetics; GWAS; MHC genes; Psoriasis; Psoriatic arthritis; Spondyloarthritis; Th17 cell signalling pathways

Indexed keywords

AMINOPEPTIDASE; ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1; FBXL19 PROTEIN; INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 6; MEMBRANE PROTEIN; TNF INDUCED PROTEIN INTERACTING PROTEIN 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLELE; ANTIGEN PRESENTATION; ARTICLE; CHROMOSOME 6P; EFFECTOR CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; EXON; GENE DELETION; GENE IDENTIFICATION; GENE INSERTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; HEREDITY; HERITABILITY; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RARE DISEASE; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; GENETIC PREDISPOSITION; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ARTHRITIS, PSORIATIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE;

EID: 84927916481     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2014.10.010     Document Type: Review

References (137)

1. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32:181-201.
2. Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis 2009;68: 664-7.
3. O'Rielly DD, Rahman P. Advances in the genetics of spondyloarthritis and clinical implications. Curr Rheumatol Rep 2013;15:347.
4. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009;61:1373-8.
5. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006;78:827-51.
6. Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw∗0602 positive and negative psoriasis patientsean analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006;126:740-5.
7. Chandran V, Rahman P. Update on the genetics of spondyloarthritiseankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol 2010;24:579-88.
8. Chandran V, Bull SB, Pellett FJ, et al. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum Immunol 2013;74:1333-8.
9. Gladman DD, Anhorn KA, Schachter RK, et al. HLA antigens in psoriatic arthritis. J Rheumatol 1986;13:586-92.
10. Gladman DD, Ziouzina O, Thavaneswaran A, et al. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol 2013;40(8):1357-9.
11. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 2012;90:636-47.
12. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008;35:1449-53.
13. Korendowych E, Ravindran J, Owen PA, et al. Disease-specific alleles of the MHC Class I related gene, MICA, are associated with type I psoriasis and psoriatic arthritis [abstract FC 10]. Br J Dermatol 2006;154:4.
14. Chandran V, Bull SB, Pellett FJ, et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatol Oxf 2014;53:233-9.
15. Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003;72:125-31.
16. Manolio TA. Bringing genome-wide association findings into clinical use. Nat Rev Genet 2013;14:549-58.
17. Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012;44:1341-8.
18. Bowes J, Orozco G, Flynn E, et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann Rheum Dis 2011;70:1641-4.
19. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041.
20. Hüffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010;42:996-9.
21. Stuart PE, Nair RP, Ellinghaus E, et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010;42:1000-4.
22. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204.
23. Ellinghaus E, Ellinghaus D, Stuart PE, et al. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet 2010;42:991-5.
24. Genetic Analysis of Psoriasis Consortium, The Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-90.
25. Zhang XJ, HuangW, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009;41:205-10.
26. Sun LD, Cheng H, Wang ZX, et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010;42:1005-9.
27. O'Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol 2011;7:718-32.
28. Yan J, Parekh VV, Mendez-Fernandez Y, et al. In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med 2006;203:647-59.
29. Birtley JR, Saridakis E, Stratikos E, et al. The crystal structure of human endoplasmic reticulum aminopeptidase 2 reveals the atomic basis for distinct roles in antigen processing. Biochemistry 2012;51:286-95.
30. Bowcock AM, Shannon W, Du F, et al. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001;10:1793-805.
31. Kersh EN. Impaired memory CD8 T cell development in the absence of methyl-CpG-binding domain protein 2. J Immunol 2006;177:3821-6.
32. Zamisch M, Tian L, Grenningloh R, et al. The transcription factor Ets1 is important for CD4 repression and Runx3 upregulation during CD8 T cell differentiation in the thymus. J Exp Med 2009;206:2685-99.
33. Chang IF, Hsiao HY. Induction of RhoGAP and pathological changes characteristic of Alzheimer's disease by UAHFEMF discharge in rat brain. Curr Alzheimer Res 2005;2:559-69.
34. Togayachi A, Kozono Y, Kuno A, et al. Beta3GnT2 (B3GNT2), a major polylactosamine synthase: analysis of B3GNT2- deficient mice. Methods Enzymol 2010;479:185-204.
35. Lories RJ, de Vlam K. Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? Curr Rheumatol Rep 2012;14:375-82.
36. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009;206:1983-94.
37. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res 2011;31:5-11.
38. Meyer O. Interferons and autoimmune disorders. Jt Bone Spine 2009;76:464-73.
39. Gotoh K, Tanaka Y, Nishikimi A, et al. Selective control of type I IFN induction by the Rac activator DOCK2 during TLRmediated plasmacytoid dendritic cell activation. J Exp Med 2010;207:721-30.
40. Piganis RA, De Weerd NA, Gould JA, et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 2011; 286:33811-8.
41. Strobl B, Stoiber D, Sexl V, et al. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci Landmark Ed 2011;16:3214-32.
42. Bijlmakers MJ, Kanneganti SK, Barker JN, et al. Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet 2011;20: 3129-37.
43. Singh H, Glasmacher E, Chang AB, et al. The molecular choreography of IRF4 and IRF8 with immune system partners. Cold Spring Harb Symp Quant Biol 2013;78:101-4.
44. Onomoto K, Jogi M, Yoo JS, et al. Critical role of an antiviral stress granule containing RIG-I and PKR in viral detection and innate immunity. PLoS One 2012;7:e43031.
45. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007;89:729-34.
46. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005;52: 710-21.
47. Li P, Schwarz EM, O'Keefe RJ, et al. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Min Res 2004;19:207-13.
48. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000;141:3956-64.
49. Mukai Y, Shibata H, Nakamura T, et al. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 2009;385:1221-9.
50. Mukai Y, Nakamura T, Yoshioka Y, et al. Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009;65: 295-8.
51. Tesmer LA, Lundy SK, Sarkar S, et al. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
52. Israël A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 2000;10:129-33.
53. Abdou AG, Hanout HM. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol 2008;35:445-51.
54. Moorchung N, Kulaar JS, Chatterjee M, et al. Role of NF-kB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens. Int J Dermatol 2014;53:570-4.
55. Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009;30:383-91.
56. DeSelm CJ, Takahata Y, Warren J, et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem 2012;113:2895-902.
57. Wang C, Wu L, Bulek K, et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013;14:72-81.
58. Verstrepen L, Carpentier I, Verhelst K, et al. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. Biochem Pharmacol 2009;78:105-14.
59. De Molfetta GA, Lucíola Zanette D, Alexandre Panepucci R, et al. Role of NFKB2 on the early myeloid differentiation of CD34+ hematopoietic stem/progenitor cells. Differentiation 2010;80:195-203.
60. Blonska M, Lin X. NF-kB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 2011;21:55-70.
61. Jayne S, Rothgiesser KM, Hottiger MO. CARM1 but not its enzymatic activity is required for transcriptional coactivation of NF-kappaB-dependent gene expression. J Mol Biol 2009;394:485-95.
62. Lowenstein CJ, Padalko E. iNOS (NOS2) at a glance. J Cell Sci 2004;117:2865-7.
63. Fu B, Li S, Wang L, et al. The ubiquitin conjugating enzyme UBE2L3 regulates TNFa-induced linear ubiquitination. Cell Res 2014;24:376-9.
64. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009;11:625-30.
65. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9.
66. Ryan C, Abramson A, Patel M, et al. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012;21: 473-87.
67. Cheung PF, Wong CK, Lam CW. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008;180: 5625-35.
68. Bulek K, Liu C, Swaidani S, et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011;12:844-52.
69. Sønder SU, Saret S, Tang W, et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem 2011;286:12881-90.
70. Fujioka S, Niu J, Schmidt C, et al. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004;24. 7806-7619.
71. Liu C, Qian W, Qian Y, et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal 2009;2. ra63.
72. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87.
73. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-30.
74. Han G, Williams CA, Salter K, et al. A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol 2010;130:371-7.
75. Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-7.
76. Flisiak I, Chodynicka B, Porebski P, et al. Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 2002;19:121-5.
77. Flisiak I, Zaniewski P, Chodynicka B. Plasma TGF-beta1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity. Biomarkers 2008;13:549-56.
78. Nockowski P, Szepietowski JC, Ziarkiewicz M, et al. Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris. Acta Dermatovenerol Croat 2004;12:2-6.
79. BaranW, Szepietowski JC, Mazur G, et al. TGF-beta(1) gene polymorphism in psoriasis vulgaris. Cytokine 2007;38:8-11.
80. Akhurst RJ. TGF beta signaling in health and disease. Nat Genet 2004;36:790-2.
81. Suttle MM, Nilsson G, Snellman E, et al. Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor. Clin Exp Immunol 2012;169:311-9.
82. Lindroos J, Svensson L, Norsgaard H, et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J Invest Dermatol 2011;131:1110-8.
83. Yang XP, Ghoreschi K, Steward-Tharp SM, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011;12:247-54.
84. Dong C. Regulation and pro-inflammatory function of interleukin-17 family cytokines. Immunol Rev 2008;226:80-6.
85. Baran W, Szepietowski JC, Mazur G, et al. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol 2008;88:113-6.
86. Boca AN, Talamonti M, Galluzzo M, et al. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. Immunol Lett 2013;156:127-31.
87. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-50.
88. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
89. Blumberg H, Dinh H, Dean Jr C, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 2010;185:4354-62.
90. Juliá A, Tortosa R, Hernanz JM, et al. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum Mol Genet 2012;21:4549-57.
91. Rahman P, Sun S, Peddle L, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006;54:2321-5.
92. Ravindran JS, Owen P, Lagan A, et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatol Oxf 2004;43:22-6.
93. Bowes J, Ho P, Flynn E, et al. Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. Ann Rheum Dis 2012;71:313-4.
94. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
95. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-708.
96. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40.
97. Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 2011;134:8-16.
98. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin Immunol 2007;19: 372-6.
99. Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012;135:112-24.
100. Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatol Oxf 2007;46:417-25.
101. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30.
102. Zhu KJ, Zhu CY, Shi G, et al. Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis. Inflamm Res 2012;61:1149-54.
103. Cénit MC, Ortego-Centeno N, Raya E, et al. Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease. Hum Immunol 2013;74:230-3.
104. Harris TJ, Grosso JF, Yen HR, et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007;179:4313-7.
105. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121-33.
106. Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28:29-39.
107. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005;202:589-95.
108. Tanaka K, Ichiyama K, Hashimoto M, et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 2008;180: 3746-56.
109. Moisan J, Grenningloh R, Bettelli E, et al. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 2007;204: 2825-35.
110. Novatchkova M, Leibbrandt A,Werzowa J, et al. The STIR-domain superfamily in signal transduction, development and immunity. Trends Biochem Sci 2003;28:226-9.
111. Toy D, Kugler D, Wolfson M, et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006;177:36-9.
112. Shen F, Hu Z, Goswami J, et al. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006;281:24138-48.
113. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
114. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008;41:84-91.
115. Chabaud M, Lubberts E, Joosten L, et al. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001;3:168-77.
116. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359:419-29.
117. Mrabet D, Laadhar L, Sahli H, et al. Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study. Rheumatol Int 2013;33:265-6.
118. Tonel G, Conrad C, Laggner U, et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010;185: 5688-91.
119. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7.
120. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009;160:319-24.
121. Ammar M, Bouchlaka-Souissi C, Zaraa I, et al. Family-based association study in Tunisian familial psoriasis. Int J Dermatol 2012;51:1329-34.
122. Catanoso MG, Boiardi L, Macchioni P, et al. IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population. Rheumatol Int 2013;33:1165-76.
123. Prans E, Kingo K, Traks T, et al. Copy number variations in IL22 gene are associated with Psoriasis vulgaris. Hum Immunol 2013;74:792-5.
124. Tohyama M, Hanakawa Y, Shirakata Y, et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009;39:2779-88.
125. Saeki H, Hirota T, Nakagawa H, et al. Genetic polymorphisms in the IL22 gene are associated with psoriasis vulgaris in a Japanese population. J Dermatol Sci 2013;71:148-50.
126. Nikamo P, Cheuk S, Lysell J, et al. Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL-22 production in T cells. J Invest Dermatol 2014;134:1535-41.
127. Hoeve MA, Savage ND, de Boer T, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006;36:661-70.
128. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-7.
129. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-3.
130. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009;15:1013-5.
131. He Z, Jin L, Liu ZF, et al. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br J Dermatol 2012;167:191-3.
132. Warren RB, Smith RL, Flynn E, et al., UKRAG Consortium. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol 2011;164:660-4.
133. Hollox EJ. Copy number variation of beta-defensins and relevance to disease. Cytogenet Genome Res 2008;123: 148-55.
134. Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factoralpha- treated human neutrophils. Immunology 2004;111:273-81.
135. de Cid R, Riveira-Munoz E, Zeeuwen PL, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-5.
136. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365:620-8.
137. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012;90:784-95.